Clinical Trials Browser

Colorectal Neoplasms × sintilimab × Clear all

NCT07506109 2026-04-07

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

Phase 2 Recruiting

Gastrointestinal

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT05427487 2026-03-25

Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

Phase 1 Recruiting

GastrointestinalGynecologic

Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT06497985 2026-03-19

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05171660 2026-02-17

Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

Phase 3 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07398326 2026-02-09

Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06356584 2025-06-26

Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06794086 2025-05-13

SPARKLE-L

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06698757 2025-03-13

Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal Cancer

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06456515 2025-02-17

Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC

Phase NA Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06543836 2024-08-09

ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT04271813 2024-04-23

Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT06347198 2024-04-04

Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer

Phase EARLY_PHASE1 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT06195670 2024-01-08

Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

Phase 1/2 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06120127 2023-11-07

IMPROVE

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT04724239 2023-08-01

Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT04194359 2023-03-17

Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT04304209 2023-02-01

Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer

Phase 2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05236972 2022-12-30

PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05524155 2022-09-01

Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT05438108 2022-06-29

SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT05292417 2022-03-31

Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT04535024 2021-05-11

The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT04695470 2021-01-07

Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer Patients

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms